The Interaction of Diabetes and Tuberculosis

van Crevel, R.; Critchley, J.A. The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice. Trop. Med. Infect. Dis. 2021, 6, 8.

  • Increased Risk: People with diabetes have a 2–3 times higher risk of developing TB compared to non-diabetic individuals.
  • Altered TB Presentation: Diabetes alters TB symptoms, with more severe presentations, higher TB scores, more cavitation, and a longer time to achieve smear or culture negativity.
  • Worsened Treatment Outcomes: Diabetes, especially when poorly controlled, worsens TB treatment outcomes, including doubling the risk of death during treatment.
  • Increased Bacterial Load: Diabetes may increase the bacterial load of Mycobacterium tuberculosis, leading to prolonged infectiousness.
  • Screening Challenges: Screening diabetes patients for TB may have low yield, except in high TB incidence areas. Risk scores for identifying undiagnosed diabetes among TB patients need further validation.
  • Drug Interactions: Rifampicin increases the metabolism of many diabetes medications, requiring dose adjustments or substitutions, except for metformin.
  • Metformin Advantages: Metformin remains the preferred glucose-lowering agent for diabetes patients with TB due to its low hypoglycemia risk, low cost, and lack of significant interaction with rifampicin.
  • Metformin Disadvantages: Metformin can cause gastrointestinal side effects, which may worsen with TB drugs, and carries a rare but serious risk of lactic acidosis, especially in patients with decreased kidney function.
  • Infection Control: TB patients should avoid specialized diabetes services during early TB treatment to prevent Mycobacterium tuberculosis transmission.

    • Some Outstanding Clinical and Population Health Questions Related to Diabetes-Associated TB:

    • Are there any differences in the risk of TB disease or treatment outcomes between people with type 1 and type 2 diabetes?
    • Is intermediate hyperglycemia ("pre-diabetes") a risk factor for TB disease and death?
    • Does diabetes (type 1 or type 2) or intermediate hyperglycemia affect the risk of LTBI?
    • What are the costs, risks, and benefits of preventive therapy for LTBI, both for individuals and populations?
    • How can health systems be organized to strengthen multi-morbidity care and prevention, e.g., through the strengthening of primary care?
    • How should routine medications to reduce CVD risk be used in patients with TB and DM, and when should they be introduced?
    • Which anti-DM medications should be used in TB patients? How and when should they be introduced and adjusted for dosage?
    • Should TB treatment be intensified or prolonged in people with diabetes?
    • How can smoking cessation and relapse prevention interventions be incorporated into TB-DM management?
    • Do TB survivors with diabetes face long-term sequelae and higher risks, even after successful treatment completion (e.g., TB recurrence, cardiovascular or pulmonary disease, or poor quality of life/disability)? How should they be followed up after the completion of treatment?
    • How can the TB community advocate for investment in diabetes prevention and management?

     

    Comments

    Post a Comment

    Popular posts from this blog

    Nutritional status in patients with TB and DM

    Patel, D.G., Baral, T., Kurian, S.J., Malakapogu, P., Saravu, K. and Miraj, S.S., 2024. Nutritional status in patients with tuberculosis and diabetes mellitus: A comparative observational study.  Journal of Clinical Tuberculosis and Other Mycobacterial Diseases ,  35 , p.100428. Cardiovascular disease prevalence was highest in the DM group, followed by the TB-DM group. Anaemia was more prevalent in the TB-DM group. Smoking and alcohol use were most common in the TB group, followed by the TB-DM group. See also: TB and kidney function impairment In the TB-DM group, HbA1c levels indicated poor diabetic control (10.47%), higher than in the DM group (8.17%). FBS was also above normal in the TB-DM group, followed by the DM group. Although there were no significant differences in nutritional parameters like albumin, globulin, and total proteins, vitamin B12 levels were highest in the TB-DM group. Notably, 95.83% of patients in the TB-DM group had HbA1c > 6.5, with similarly high FBS and RB
    Read more

    Scientific advances and the end of tuberculosis

    Reid, M., Agbassi, Y.J.P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D. and Churchyard, G., 2023. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.  The Lancet ,  402 (10411), pp.1473-1498. Progress toward ending tuberculosis varies greatly across countries, with some achieving substantial improvements and others making minimal progress. Key challenges include frail health systems, underinvestment, and reliance on one-size-fits-all approaches. Insufficient case finding and diagnosis remain the most significant issues in high-burden countries, where only 38% of all tuberculosis cases were tested with WHO-recommended rapid molecular diagnostics in 2021. Two-thirds of tuberculosis deaths occurred in just eight countries, with over half of these in India, Indonesia, and Nigeria. Despite these challenges, some sub-Saharan African countries have seen improvements in tubercul
    Read more

    Impact of diabetes on tuberculosis and MDRTB susceptibility

    There is a significant association between diabetes mellitus (DM) and multidrug-resistant tuberculosis (MDR-TB). TB patients without DM have a lower risk of developing MDR-TB compared to those with DM. Factors contributing to MDR-TB emergence in TB patients with DM include: Impaired immune function Altered microbial genomics Uncontrolled glucose levels, increasing susceptibility to MDR-TB Compromised phagocytic activity and reduced chemotactic response Increased oxidative species and microbe proliferation Altered drug disposition Higher likelihood of non-adherence to treatment TB patients with DM also experience higher treatment failure rates compared to those without DM. Most information on these associations is based on self-reported data or patient health records, which may introduce assessment errors Rehman Au, Khattak M, Mushtaq U, Latif M, Ahmad I, Rasool MF, Shakeel S, Hayat K, Hussain R, Alhazmi GA, Alshomrani AO, Alalawi MI, Alghamdi S, Imam MT, Almarzoky Abuhussain SS, Khayya
    Read more